Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal

Amneal Pharmaceuticals agreed to acquire Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion, expanding its biosimilars business. The transaction is strategically positive for Amneal’s healthcare and biotech footprint and could improve its long-term competitive positioning in biosimilars. The announcement is likely to be stock-moving for Amneal and relevant to the broader pharmaceutical M&A landscape.

Analysis

Amneal Pharmaceuticals agreed to acquire Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion, expanding its biosimilars business. The transaction is strategically positive for Amneal’s healthcare and biotech footprint and could improve its long-term competitive positioning in biosimilars. The announcement is likely to be stock-moving for Amneal and relevant to the broader pharmaceutical M&A landscape.